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SUMMARY
Gastrointestinal stromal tumours (GISTs) are generally rare
but are known to be the most common mesenchymal
tumours of the gastrointestinal tract. We present a case of
a patient who presented with persistent obstructive
gastrointestinal and urological symptoms, a sense of
incomplete evacuation and bleeding per rectum.
A colonoscopy was performed and a biopsy was taken of
a submucosal mass in the distal rectum that revealed a
GIST with positive KIT immunostaining. A positron
emission tomography (PET)/CT scan showed a large
metabolically active distal rectal tumour of 8 cm with
macroscopic invasion of surrounding structures.
Neoadjuvant therapy with receptor tyrosine kinase
inhibitor imatinib (400 mg orally daily) was initiated and
an excellent partial response consisting of a significant
decrease in the size of the tumour with complete
metabolic resolution was observed within 3 months.
Six months after initiation of the neoadjuvant therapy a
rectum resection with manual side-to-end coloanal
anastomosis was performed. Pathology showed a GIST of
5 cm located 0.1 cm from the distal section plane. Our
case shows that in patients with a large invasive distal
rectal GIST, neoadjuvant imatinib therapy can facilitate
anal sphincter sparing surgery.
BACKGROUND
Gastrointestinal stromal tumours (GISTs) are rare
tumours that constitute around 1% of all primary
gastrointestinal cancers.1 Specific mutations in the
so-called KIT oncogene are the most common cause
of the development of this tumour.2 Imatinib is an
inhibitor of the protein encoded by the KIToncogene
and was approved for the treatment of GIST tumours
in 2002.3 We present a case of a 40-year-old patient
referred to our department with a large GIST in the
distal rectum who received neoadjuvant therapy
with imatinib. A significant decrease in the size of
the tumour was seen after the oral therapy.
Consequently, the patient was able to undergo anal
sphincter sparing surgery without the creation of an
ileostoma. Our case shows that in patients with a
large invasive distal rectal GIST, mutilating operations
such as abdominoperineal resection and pelvic exen-
teration can be avoided.
CASE PRESENTATION
A 40-year-old man with an unremarkable medical
history presented in another hospital with a history
of difficulty of defaecation, perineal pain, a sense
of incomplete evacuation and bleeding per rectum
for 2 months. The patient also mentioned a history
of intermittent difficulty in micturition with no
change in urine colour and odour. On rectal exam-
ination, a mass was felt originating from the anter-
ior wall of the rectum.
INVESTIGATIONS
Rectoscopy showed a ventral submucosal mass that
was partially ulcerated. Laboratory tests revealed
normocytic normochromic anaemia (12.9 g/dL
(14–18 g/dL)), tumour markers within normal ranges
(carcinoembryonic antigen 0.6 ng/mL (<3.8 ng/mL))
and normal prostate-specific antigen 1.19 ng/mL
(<2.00 ng/mL)). To exclude prostate cancer, transrec-
tal ultrasonography was performed and a biopsy was
taken that showed no atypia on histological
investigation.
A month later, the patient underwent a colonos-
copy and a biopsy was taken from the rectum. This
time the biopsy showed neoplasia of mesenchymal
cells with no visualised mitosis and the presence of
the immunological marker CD117 (KIT), indicative
of a GIST. Further evaluation with pelvic positron
emission tomography (PET)/CT and pelvic MRI
showed a large metabolically active rectal tumour
with a maximum diameter of 8 cm originating
from the anterior wall of the distal rectum with
macroscopic invasion of surrounding structures and
no evidence of distant metastasis (figure 1).
TREATMENT
Neoadjuvant therapy was initiated with imatinib
400 mg orally daily. The therapy was scheduled for
6 months and would be followed by surgical removal
of the remaining tumour. On the 10th day after initi-
ation of the neoadjuvant therapy the patient was
referred to our hospital. The patient reported early
signs of response as his obstructive symptoms had
already disappeared since starting imatinib. A
follow-up whole-body PET/CT after 3 months of
neoadjuvant treatment showed a remarkable decrease
in tumour size to 5 cm in diameter with complete
metabolic response. Unfortunately, 4 months after the
initiation of neoadjuvant therapy the patient developed
generalised erythematous papules with severe itching
mainly within 1 h of taking imatinib. The dermatolo-
gist was consulted, and topical and systemic treatment
of the skin symptoms was started. Owing to the per-
sistence of the skin symptoms, the dose of imatinib
was adjusted to 400 mg imatinib orally every other
day, which led to better tolerance of the drug, and the
operation was rescheduled (Naranjo score = 7).4
Kramp KH, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2014-207775 1
Novel treatment (new drug/intervention; established drug/procedure in new situation)
A preoperative MRI of the pelvic floor performed after
5 months of treatment confirmed a significant decrease in tumour
size (figure 2). The lower border of the tumour was at the level of
the anal sphincter and there was no macroscopic invasion of sur-
rounding structures. After 6 months of neoadjuvant therapy the
patient underwent a rectum resection with manual side-to-end
coloanal anastomosis. The mesorectal plane was easily dissected.
A Lone Star Retractor was used to perform a sleeve mucosectomy
through the anal canal with resection of the upper border of the
internal anal sphincter that was still infiltrated by the tumour
(figure 3). No ileostoma was created because the anastomosis had
a good vascularisation and was traction free.
OUTCOME AND FOLLOW-UP
Postoperative macroscopic examination by the pathologist
showed a maximum tumour diameter of 5 cm located 0.1 cm
from the distal section plane. Microscopic examination showed
negative section planes, no lymphovascular invasion and a
mitotic count of 2/50 high power field (HPF). Mutational ana-
lysis revealed a p.W557-V559delinsF mutation in exon 11 of
the KIT gene.
DISCUSSION
What is a GIST?
GISTs are part of the large heterogeneous family of soft tissue
sarcomas. GIST cells share some morphological and immunohis-
tochemical similarities with the pacemaker cells of the gastro-
intestinal tract that regulate peristalsis, the interstitial cells of
Cajal,5 GIST cells and the interstitial cells of Cajal are therefore
thought to have a common ancestry. They can be found in the
stomach (51%), jejunum and ilium (36%), colon and rectum
(5–7%), but can also occur extra-gastrointestinally in the mesen-
tery or omentum in rare cases.1 6
Most GISTs are caused by sporadic mutations of the KIT or
PDGFRA oncogene.7 The mean age at which they are found is
usually between 55 and 68 years, but GISTs can also occur in
children with rare hereditary syndromes.8 Patients with a GIST
usually have non-specific symptoms of gastrointestinal bleeding
(33%), abdominal pain (19%), anaemia (9%), abdominal mass
(7%) and obstruction (3%).9 In our case, a mass was felt in the
anterior rectum, which could raise the suspicion of the presence
of a prostate tumour. Some authors therefore advocate including
GIST in the differential diagnoses of prostate lesions to avoid
delayed diagnosis and/or suboptimal treatment.10
Diagnosis
The diagnostic work up of a symptomatic colorectal tumour
often begins with a colonoscopy. A GIST can be seen as a sub-
mucosal mass and a biopsy with sufficient tissue sampling can
confirm the diagnosis. The biopsy usually shows a spindle, epi-
thelial or mixed cell type. The mitotic count is an important
prognostic factor because it is used as a determinant of the
aggressiveness of the tumour. Immune histopathology is per-
formed to identify the presence of the CD117 (KIT) antigen,
which is indicative of a GIST, but can also occur in other malig-
nancies and in normal tissue, such as in the interstitial cells of
Cajal.11
A stromal tumour can also be diagnosed on PET/CT imaging;
it is usually seen as an exophytic mass that heterogeneously
enhances with intravenous contrast because of its high vascular-
isation.12 The high anatomic definition of MRI can be helpful
in the evaluation of resectability. Contrary to adenocarcinoma,
GISTs rarely metastasise to regional lymph nodes and unlike
Figure 1 First positron emission
tomography (PET)/CT scan and MRI.
(Left) A transversal cross section of the
PET/CT scan showing a large metabolic
active tumour. (Right) A sagittal cross
section of the MRI showing the
compression effect on the rectum,
prostate and seminal vesicles.
Figure 2 Preoperative MRI. (Left)
A transversal cross section. (Right)
A sagittal cross-section. Tumour size
39 mm transverse × 38 mm anterior
posterior × 53 mm craniocaudal.
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other soft tissue sarcomas, they often metastasise to the liver
and peritoneum, and rarely to the lung.13 Extra-abdominal
metastases are rare but frequently occur during late stages of
advanced disease after long periods of treatment with imatinib
and other tyrosine kinase inhibitors. Extra-abdominal metastases
and multifocal primaries are also associated with the few
reported cases of hereditary GIST syndromes (eg, Carney’s
triad).14
Prognosis
It is generally accepted that all GISTs with clinical symptoms or a
tumour size above 1 cm have the potential to behave malignantly.
The determination of the degree of aggressiveness of the tumour is
controversial. It has been shown that the Miettinen and Lasota risk
classification is the most predictive.15 16 This classification is based
on the size, mitotic counts and anatomical site of the tumour.
Other factors that determine the aggressiveness of the tumour are
the presence of synchronous metastasis, rupture during surgery
and mutational subtype.17–19 Although R0 resection should always
be obtained if possible, the microscopic resection margin does not
seem to be a crucial predictor of survival.7 20–22
Histopathology and mutational analysis
In approximately 90% of GISTs there is a mutation in the KIT
gene, leading to overexpression of KIT, a transmembrane stem
cell growth factor sensitive tyrosine kinase receptor.2 The over-
expression leads to constitutional activation of oncogenic cell
pathways that are involved in proliferation, with uncontrolled
cell growth as a result. The antigen CD117, a part of this tyro-
sine kinase receptor, is used as a cell surface marker in the iden-
tification of GISTs during pathologic investigation.2 23 24
Contrary to other mesenchymal tumours, GISTs are almost
always negative for desmin and S-100 protein.24
Imatinib
GISTs are unresponsive to chemotherapy and not very sensitive to
radiotherapy. The only option for treatment before the introduction
of imatinib in clinical practice was total resection of the tumour and
its metastases. During early phase 1 and 2 studies, imatinib was
found to inhibit the uncontrolled growth of GIST cells that express
tyrosine kinase receptors encoded by the KIT or PDGFRA onco-
gene.25 Further studies have shown that the metabolic activity of the
KIT/PDGFRA mutation positive tumours can decrease as early as
24 h after initiation of imatinib and the size of the tumour can
decrease markedly in months, as was seen in our case.26 Primary
imatinib resistance to neoadjuvant imatinib therapy is found in 50%
of PDGFRA mutation positive tumours, 33% of wild-type tumours
and 9% of KIT mutation positive tumours.18 It is therefore import-
ant to identify the exact mutation because certain mutations are
non-responsive to tyrosine kinase inhibitors.
Neoadjuvant imatinib increases the chance of successful surgery
as smaller tumours can be resected more easily from surrounding
anatomical structures and have a decreased chance of rupture
during surgery.27 The duration of neoadjuvant therapy is contro-
versial. Neoadjuvant therapy can in theory be continued until the
regression of the tumour size or metabolic activity reaches a
plateau phase, but the risk of resistance through the development
of secondary KIT mutations during this stage should be avoided as
far as possible.27 Most physicians therefore advocate a neoadjuvant
treatment duration of 4–12 months, when the maximum shrink-
age and metabolic response of the tumour has been achieved, and
the risk of secondary resistance is still low.7
Follow-up
Unfortunately, there is limited literature regarding the recur-
rence and mortality of surgically treated patients with colorectal
GISTs who received preoperative imatinib. In a study by
Machlenkin et al28 of 12 patients with a rectal GISTs, 71% of
the patients who underwent surgery after neoadjuvant imatinib
and adjuvant imatinib in the case R1 or R2 resection had no
clinical or radiological recurrence, and 86% of all patients were
alive after a median follow-up of 32 months. In a study by
Rutkowski et al,7 33 patients operated for rectal GIST after
neoadjuvant imatinib showed a 3-year disease free survival rate
of 88%. In a recent study, 5 patients underwent laparoscopic
intersphincteric resection after neoadjuvant imatinib.29 No
recurrence was observed after a media follow-up of 36 months.
It is generally accepted that there is no indication for adjuvant
therapy for low-risk rectal GISTs (<5 cm and <5/50 HPF accord-
ing to the Miettinen and Lasota risk classification). Adjuvant ima-
tinib therapy should be considered in patients with an
intermediate to highly aggressive tumour and in the case of a
resection with a microscopic (R1) or macroscopic residual
tumour (R2).30 Although the GIST in our case can be categorised
as a tumour of intermediate aggressiveness according to the NIH
classification, the patient was advised not to start with adjuvant
imatinib because of poor tolerance of the agent. The patient had
concerns about the possibility of suboptimal treatment by not
starting adjuvant imatinib therapy, but when confronted with the
typical duration of adjuvant treatment of 3 years (or even
longer), the patient agreed with strict follow-up.31 At 3-month
follow-up the patient reported no symptoms of incontinence and
had no radiological signs of local recurrence or metastasis.
Learning points
▸ Rectal gastrointestinal stromal tumours (GISTs) are rare
tumours that can present with gastrointestinal and
urological symptoms.
▸ Adequate immunohistochemistry of a biopsy is an important
diagnostic tool because mutational variants of KIT and
PDGFRA mutation positive tumours are responsive to the
tyrosine kinase inhibitor imatinib.
▸ Neoadjuvant treatment with imatinib can effectively reduce
the size of a GIST and thereby minimise damage to
surrounding structures during surgery.
Figure 3 Dissection of the tumour with the Lone Star retractor.
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